BC Week In Review | Aug 5, 2013
Clinical News

AMG 747: Development discontinued

Amgen disclosed in its 2Q13 earnings that it discontinued a Phase II program for AMG 747 to treat schizophrenia. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif.   Product: AMG 747   Business: Neurology   Molecular target:...
Items per page:
1 - 1 of 1